Medizinische Hochschule Hannover

The Department of Anaesthesiology and Intensive Care at the Medizinische Hochschule Hannover is advancing diagnostic and therapeutic technologies to improve critical care outcomes. Research focuses on evaluating new devices and precision‑medicine tools for patients in intensive settings.

• high‑resolution ultrasound for lung monitoring
• wearable sensors for hemodynamic tracking
• targeted drug‑delivery catheters

With 396 active trials and 183 investigators, the site integrates cutting‑edge equipment into everyday clinical practice.

Studies target severe bacterial and fungal infections in critically ill patients, aiming to identify optimal antimicrobial regimens and reduce mortality.

• multidrug‑resistant Staphylococcus aureus bacteremia
• invasive candidiasis in ICU settings
• novel antifungal combination therapies

The programme supports rapid diagnostics to guide early, effective treatment.

Research explores innovative approaches for heart failure, coronary syndromes, and pulmonary hypertension, testing new pharmacologic and device‑based interventions.

• reduced‑ejection‑fraction heart failure therapies
• post‑myocardial infarction remodeling inhibition
• pulmonary arterial hypertension targeted agents

The department leverages its intensive‑care expertise to assess cardiovascular risk and treatment response.

The site conducts trials on rare genetic and neonatal conditions, focusing on early diagnosis and therapeutic correction.

• gene‑therapy for congenital metabolic disorders
• neonatal lung disease ventilation strategies
• prenatal screening for hereditary anomalies

Collaboration with pediatric specialists enables comprehensive care from birth onward.

Investigations aim to improve outcomes for severe liver and gastrointestinal disorders through novel pharmacologic and procedural interventions.

• acute‑on‑chronic liver failure management
• cholangiocarcinoma targeted therapy trials
• non‑alcoholic steatohepatitis (NASH) anti‑fibrotic agents

Intensive‑care monitoring supports safety assessments for high‑risk hepatic patients.

Clinical work evaluates advanced treatments for retinal and ocular conditions, seeking to preserve vision and reduce disease progression.

• anti‑VEGF agents for diabetic macular edema
• gene‑editing approaches for inherited retinal dystrophies
• low‑dose atropine for myopia control in children

The department’s imaging suite enables precise assessment of therapeutic impact.

Trials address obstetric emergencies and gynecologic disorders, evaluating interventions that improve maternal and fetal outcomes.

• pre‑eclampsia prevention with novel antihypertensives
• uterine fibroid minimally invasive ablation
• post‑partum hemorrhage blood‑conserving strategies

Critical‑care expertise ensures rapid response to life‑threatening complications.

Focus is on disorders of blood and lymphatic systems, testing therapies that modulate coagulation, immunity, and cellular proliferation.

• immune‑mediated thrombotic thrombocytopenic purpura treatment
• polycythemia vera phlebotomy reduction trials
• novel agents for chronic lymphocytic leukemia

Hematologic monitoring is integrated into the intensive‑care workflow.

Research targets autoimmune and inflammatory conditions, evaluating biologics and small molecules that restore immune balance.

• IL‑6 inhibition for systemic inflammatory syndromes
• JAK‑inhibitor safety in severe rheumatoid disease
• cell‑based therapy for graft‑versus‑host disease

The department’s expertise in cytokine storms informs trial design.

Clinical programs evaluate novel treatments for prostate and testicular disorders, aiming to improve urinary function and oncologic control.

• targeted therapy for advanced prostate cancer
• minimally invasive surgery for benign prostatic hyperplasia
• immunotherapy for testicular germ‑cell tumors

Intensive monitoring supports safety assessment of systemic agents.

The site investigates therapies for bone, joint, and muscle disorders, emphasizing functional recovery and pain reduction.

• biologic agents for axial spondyloarthritis
• regenerative cell therapy for severe burns
• novel analgesics for postoperative musculoskeletal pain

Physical‑rehabilitation units collaborate to track long‑term outcomes.

Oncology research spans solid tumors and hematologic malignancies, testing innovative drugs, immunotherapies, and combination regimens.

• checkpoint inhibitor plus tyrosine‑kinase inhibitor for hepatocellular carcinoma
• CAR‑T cell therapy for refractory acute lymphoblastic leukemia
• targeted therapy for BRCA‑mutated breast cancer

The intensive‑care unit provides critical support for high‑risk oncology patients.

Trials aim to slow neurodegeneration and improve neurological function through disease‑modifying agents and supportive care.

• SOD1‑targeted therapy for amyotrophic lateral sclerosis
• dopaminergic treatment optimization for Parkinson’s disease
• neuroprotective strategies after subarachnoid hemorrhage

Advanced neuro‑monitoring guides safety evaluations throughout the studies.

Research focuses on metabolic disorders, evaluating agents that modulate lipid, glucose, and protein pathways.

• RNA‑based therapy for alpha‑1 antitrypsin deficiency
• novel lipid‑lowering agents for hypercholesterolemia
• metabolic modulators for non‑alcoholic steatohepatitis

Metabolic profiling is incorporated into trial endpoints.

Clinical work targets ear, nose, and throat conditions, testing interventions that improve airway patency and auditory function.

• biologic treatment for chronic rhinosinusitis
• novel antihistamine for severe allergic rhinitis
• gene therapy for hereditary hearing loss

Endoscopic expertise facilitates precise delivery of investigational agents.

Studies address complex clinical presentations, aiming to refine diagnostic criteria and therapeutic pathways for ambiguous symptom clusters.

• biomarker‑driven stratification of systemic inflammatory response syndrome
• clinical scoring systems for sepsis severity
• multimodal pain assessment tools for intensive‑care patients

Comprehensive data collection supports personalized medicine approaches.

The department evaluates therapies for acute and chronic lung conditions, including infections, fibrosis, and pulmonary hypertension.

• antimicrobial regimens for multidrug‑resistant pneumonia
• antifibrotic agents for idiopathic pulmonary fibrosis
• pulmonary vasodilators for interstitial lung disease‑associated hypertension

High‑flow oxygen and ventilation strategies are integral to safety monitoring.

Research focuses on autoimmune skin disorders and connective‑tissue pathologies, testing biologics and small molecules that modulate inflammation.

• IL‑4/IL‑13 inhibition for severe atopic dermatitis
• targeted therapy for systemic sclerosis‑related skin fibrosis
• novel antihistamines for chronic urticaria

Dermatologic assessments are coordinated with critical‑care monitoring.

The site investigates antiviral strategies for chronic and acute viral infections, emphasizing safety in immunocompromised hosts.

• direct‑acting antivirals for hepatitis C eradication
• immune‑modulating therapy for chronic hepatitis B
• novel agents for severe COVID‑19 respiratory failure

Viral load monitoring guides therapeutic adjustments throughout trials.

Investigations explore fundamental cellular processes that underlie disease, providing a mechanistic basis for therapeutic innovation.

• cell‑death pathways in sepsis‑induced organ failure
• immune checkpoint regulation in acute inflammation
• metabolic reprogramming of activated fibroblasts

Translational studies link laboratory findings to patient outcomes.

Focused research deciphers immune signaling cascades, aiming to identify targets that can be modulated to treat autoimmunity and hyperinflammation.

• IL‑6 pathway blockade in cytokine release syndrome
• complement inhibition for immune‑complex glomerulonephritis
• T‑cell exhaustion reversal in chronic viral infection

Immunophenotyping is performed on serial blood samples from trial participants.

Clinical programs assess metabolic modulators that influence energy balance, lipid handling, and glucose homeostasis in acute and chronic disease.

• AMPK activators for acute kidney injury recovery
• fatty‑acid oxidation inhibitors for non‑alcoholic fatty liver disease
• glucose‑lowering agents in critically ill patients

Metabolic profiling supports dose‑optimization decisions.

Trials investigate hormonal and renal physiology to improve outcomes in pregnancy‑related disorders and urinary dysfunction.

• vasopressin antagonists for hyponatremia in heart failure
• novel agents for neurogenic detrusor overactivity
• hormonal modulation for refractory polycystic kidney disease

Endocrine and renal labs are integrated into the trial monitoring plan.

The department participates in studies targeting neuropsychiatric conditions, evaluating pharmacologic and behavioral interventions for symptom relief.

• dopamine‑modulating therapy for Tourette syndrome
• glutamate‑receptor antagonists for borderline personality disorder
• cognitive‑behavioral program adjunct to medication in major depression

Mental‑health specialists collaborate to ensure comprehensive patient support.